Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GamEvac-Combi immunogenicity study in adults in Guinea
PACTR201702002053400Recruiting
- Sponsor
- Gamaleya Center
- Start
- Jun 2017
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Trial of GamEvac-Combi in Ebola virus disease (EVD) (2 arms), sponsored by Gamaleya Center. Primary endpoint: Duration of immunity after vaccination. Started Jun 2017; status: recruiting.
02
Drugs
GamEvac-Combi
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on PACTR201702002053400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201702002053400.